Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivative

Details Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivative Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivative

1996-10-07

1998-11-10

Lambkin, Deborah C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514438, 514461, 514447, 514448, 514471, 514472, 514473, 549 61, 549 62, 549 68, 549 70, 549 74, 549449, 549450, 549452, 549 66, 549 69, 549 72, 549 73, 549 75, 549 76, 549 77, 549 79, 549455, 549 63, 549 64, 549 65, A61K 3138, A61K 3134, C07D33338, C07D30738

Patent

active

058344985

ABSTRACT:
The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by the following formula I: ##STR1## wherein wavy line attachments indicate either the alpha (.alpha.) or beta (.beta.) configuration; hatched segments indicate .alpha. configuration, solid triangles are used to indicate .beta. configuration, dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R.sup.1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of --OR.sup.1 and --N(R.sup.1).sub.2, Y is .dbd.O or represents 2 hydrogen radicals. Certain of the compounds represented by Formula I comprise another aspect of the present invention.

REFERENCES:
patent: 3845115 (1974-10-01), Lincoln, Jr. et al.
patent: 3847967 (1974-11-01), Lincoln, Jr. et al.
patent: 3853950 (1974-12-01), Lincoln et al.
patent: 4256745 (1981-03-01), Skuballa et al.
patent: 4304783 (1981-12-01), Beck et al.
patent: 4585791 (1986-04-01), Faustini et al.
patent: 4599353 (1986-07-01), Bito
patent: 4994274 (1991-02-01), Chan et al.
patent: 5006539 (1991-04-01), Jones et al.
patent: 5028624 (1991-07-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5238961 (1993-08-01), Woodward et al.
patent: 5270049 (1993-12-01), Chan, II et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5321128 (1994-06-01), Sternschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Strenschantz et al.
patent: 5422369 (1995-06-01), Sternschantz et al.
C. Liljebris et al, Derivatives of 17-Phenyl-18, 19, 20-trinorprostaglandin F-2-alpha Isopropyl Esters: Potential Antiglaucoma Agents, J. Med. Chem. vol. 38, No. 2, Jan. 20, 1995, pp. 289-304.
Starr, M.S., Exp. Eye Res. 1971, 11 pp. 170-177.
Bito, L.Z. Biological Protection with Prostaglandins, Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1995, pp. 231-252.
Bito, L.Z. Applied Pharmacology in the Medical Treatment of Glaucoma, Drance, S.M. & Neufeld, A.H. eds., New York, Brune & Stratton, 1984, pp. 477-505.
Nilsson et al, Inv. Ophthalmol. Vis. Sci. 28 (suppl), 1987, p. 284.
Bito, L.Z., Arch. Ophthalmol. 105, 1987, 1036.
Siebold et al, Prodrug, 5, 1987, 3.

Affiliated with

Also associated with

Rating

Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1517176